The Singapore Food Agency initiated the ongoing recall after Food Standards Australia New Zealand raised warnings regarding potential foreign metal fragments in the confectionery. The order covers multiple varieties of 150g chocolate-covered blueberries and raspberries with shelf-life dates stretching into early 2028. Customers who already purchased these treats are urged not to consume them and to consult doctors if they experience health issues.
Key points
Consumers holding the affected chocolate products should not eat them and should seek med…: Consumers holding the affected chocolate products should not eat them and should seek medical advice if they have health concerns.
Customers looking for additional information or assistance are directed to contact their…: Customers looking for additional information or assistance are directed to contact their original point of purchase.
The contamination alert spans all batches of the designated dark, white, and milk chocola…: The contamination alert spans all batches of the designated dark, white, and milk chocolate-coated blueberry and raspberry items.
Sources checked by our analysis pipeline: 1
SINGAPORE – The Singapore Food Agency (SFA) has recalled various chocolate-covered fruit products under the Bomberry brand over concerns that they may contain metal.
The affected products are Bomberry Natural Blueberries + Belgian Chocolate (150g) in the flavours Dark Chocolate and White & Milk Chocolate, and Bomberry Natural Raspberries + Belgian Chocolate (150g) in the flavours White & Dark Chocolate and White & Milk Chocolate. All four products originated from Australia.
The recall covers products with “best before” dates up to and including Jan 20, 2028.
SFA has directed the importer, Little Farms, to recall the affected products as a precautionary measure, following an earlier recall by Food Standards Australia New Zealand. The recall is ongoing.
Those who have bought the affected products should not consume them, SFA said. Those who have consumed them and have concerns about their health should seek medical advice.
Consumers may contact their point of purchase for enquiries, the agency added.
Federal regulators have granted licensed physicians and pharmacies temporary clearance to formulate six experimental compounds without facing penalties. The decision covers popular recovery treatments like BPC-157 and TB-500, marking a notable policy shift by the administration. This move proceeds despite warnings from agency researchers regarding the lack of data backing the safety or effectiveness of these substances.
A top Department of Health and Human Services official challenged conventional academic publishing models during a Wednesday address on restoring credibility to the scientific community. The former Great Barrington Declaration co-author argued that selective publication by journals damages institutional trust, while also linking pandemic-era restrictions to recent disease outbreaks. However, his assertions on lockdown impacts run contrary to consensus views held by public health experts.
Federal regulators are preparing an impending approval decision on the pharmaceutical company's emerging renal therapy. The heightened focus on safety issues comes as clinical specialists, market analysts, and investors assemble to evaluate key sector data.